XAIR (beyondair.net) Short-Term Debt to Capital
Beyond Air, Inc. (XAIR) develops innovative LungFit systems to combat pulmonary pathologies using proprietary cylinder-free gas extraction technology. This daily price chart complements data on the metric, which stands at 0.00. Beyond Air, Inc. (XAIR) is focusing on expanding its B2B segment within hospitals by deploying equipment in intensive care units. Growth is driven by penetration into the US neonatal market and increased profits from the sale of components.
AINostix - analytical breakdowns and key metrics (XAIR)
The assessment of Beyond Air, Inc. (XAIR) operational strength is based on the ratio of short-term liabilities to equity, which allows for the measurement of liquidity risk when settling loans with a maturity of up to one year. Current debt under one year relative to equity at 0.00 confirms the company's financial stability while scaling LungFit system sales across pulmonology centers, minimizing the probability of default during periods of demand volatility.